Delisting riskPopularity #5,422
ProPhase Labs (PRPH)
Operator of whole-genome sequencing, esophageal diagnostics, and OTC supplement brands.
$0.0105
After hours+0.00 (+5.00%)
At close$0.0100(+11.11%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 3 | 4 | 2 | 3 | −2 | 1 | 1 | 1 | 1 | 0 | 1 |
| Cost of revenue | 6 | 7 | 4 | 3 | 3 | −3 | 1 | 1 | 1 | 1 | 0 | 1 |
| Gross profit | 2 | −3 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| 9 | 8 | 8 | 7 | 8 | 15 | 4 | 5 | 5 | 6 | 3 | 3 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 8 | 8 | 7 | 8 | 15 | 4 | 5 | 5 | 6 | 3 | 3 | |
| General & administrative | 8 | 8 | 8 | 7 | 8 | 15 | 4 | 5 | 5 | 6 | 3 | 3 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −6 | −11 | −8 | −8 | −8 | −15 | −4 | −4 | −5 | −6 | −3 | −3 |
| 0 | 0 | −1 | −1 | −1 | −1 | −1 | 0 | −2 | −2 | −1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 1 | 1 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | −2 | 1 | 0 |
| Income before tax | −7 | −12 | −9 | −8 | −9 | −16 | −5 | −4 | −7 | −8 | −4 | −3 |
| Income tax expense | −2 | −3 | −3 | −2 | −3 | 15 | 0 | 1 | 0 | −1 | 1 | 0 |
| Net income from continuing operations | −5 | −9 | −6 | −6 | −7 | −31 | −5 | −4 | −7 | −7 | −5 | −3 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | −4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −5 | −9 | −6 | −6 | −7 | −34 | 4 | −4 | −7 | −7 | −5 | −3 |
| EPS, basic | −$3.00 | −$4.80 | −$3.50 | −$3.30 | −$3.50 | −$15.80 | $2.10 | −$1.10 | −$1.60 | −$0.87 | −$0.43 | −$0.22 |
| EPS, diluted | −$3.00 | −$4.80 | −$3.50 | −$3.30 | −$3.50 | −$15.80 | $2.10 | −$1.10 | −$1.60 | −$0.87 | −$0.43 | −$0.22 |
| Weighted average shares, basic | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 8 | 12 | 14 |
| Weighted average shares, diluted | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 8 | 12 | 14 |
| EBITDA | −5 | −9 | −7 | −6 | −5 | −14 | −3 | −4 | −4 | 1 | −2 | −2 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 3 | 1 | 2 | 1 | 1 | 5 | 1 | 1 |
| EBIT | −7 | −11 | −8 | −8 | −8 | −15 | −4 | −5 | −5 | −4 | −3 | −3 |
